BACKGROUND: Complication reporting is highly variable and nonstandardized. Therefore, it is imperative to determine the surgical outcomes of major oncologic procedures. OBJECTIVE: To describe the complications after robot-assisted radical cystectomy (RARC) using a standardized and validated reporting methodology. DESIGN, SETTING, AND PARTICIPANTS: Using the International Robotic Cystectomy Consortium (IRCC) database, we identified 939 patients who underwent RARC, had available complication data, and had at least 90 d of follow-up. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Complications were analyzed and graded according to the Memorial Sloan-Kettering Cancer Center (MSKCC) system and were defined and stratified by organ system. Secondary outcomes included identification of preoperative and intraoperative variables predicting complications. Logistic regression models were used to define predictors of complications and readmission. RESULTS AND LIMITATIONS: Forty-one percent (n=387) and 48% (n=448) of patients experienced a complication within 30 and 90 d of surgery, respectively. The highest grade of complication was grade 0 in 52%, grade 1-2 in 29%, and grade 3-5 in 19% patients. Gastrointestinal, infectious, and genitourinary complications were most common (27%, 23%, and 17%, respectively). On multivariable analysis, increasing age group, neoadjuvant chemotherapy, and receipt of blood transfusion were independent predictors of any and high-grade complications, respectively. Thirty and 90-d mortality was 1.3% and 4.2%, respectively. As a multi-institutional database, a disparity in patient selection, operating standards, postoperative management, and reporting of complications can be considered a major limitation of the study. CONCLUSIONS: Surgical morbidity after RARC is significant when reported using a standardized reporting methodology. The majority of complications are low grade. Strict reporting of complications is necessary to advocate for radical cystectomy (RC) and helps in patient counseling.
BACKGROUND: Complication reporting is highly variable and nonstandardized. Therefore, it is imperative to determine the surgical outcomes of major oncologic procedures. OBJECTIVE: To describe the complications after robot-assisted radical cystectomy (RARC) using a standardized and validated reporting methodology. DESIGN, SETTING, AND PARTICIPANTS: Using the International Robotic Cystectomy Consortium (IRCC) database, we identified 939 patients who underwent RARC, had available complication data, and had at least 90 d of follow-up. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Complications were analyzed and graded according to the Memorial Sloan-Kettering Cancer Center (MSKCC) system and were defined and stratified by organ system. Secondary outcomes included identification of preoperative and intraoperative variables predicting complications. Logistic regression models were used to define predictors of complications and readmission. RESULTS AND LIMITATIONS: Forty-one percent (n=387) and 48% (n=448) of patients experienced a complication within 30 and 90 d of surgery, respectively. The highest grade of complication was grade 0 in 52%, grade 1-2 in 29%, and grade 3-5 in 19% patients. Gastrointestinal, infectious, and genitourinary complications were most common (27%, 23%, and 17%, respectively). On multivariable analysis, increasing age group, neoadjuvant chemotherapy, and receipt of blood transfusion were independent predictors of any and high-grade complications, respectively. Thirty and 90-d mortality was 1.3% and 4.2%, respectively. As a multi-institutional database, a disparity in patient selection, operating standards, postoperative management, and reporting of complications can be considered a major limitation of the study. CONCLUSIONS: Surgical morbidity after RARC is significant when reported using a standardized reporting methodology. The majority of complications are low grade. Strict reporting of complications is necessary to advocate for radical cystectomy (RC) and helps in patient counseling.
Authors: Brian J Minnillo; Matthew J Maurice; Nicholas Schiltz; Aiswarya C Pillai; Siran M Koroukian; Firouz Daneshgari; Sim P Kim; Robert Abouassaly Journal: Can Urol Assoc J Date: 2015 Jul-Aug Impact factor: 1.862
Authors: Tudor Borza; Bruce L Jacobs; Jeffrey S Montgomery; Alon Z Weizer; Todd M Morgan; Khaled S Hafez; Cheryl T Lee; Benjamin Y Li; Hye Sung Min; Chang He; Scott M Gilbert; Jonathan E Helm; Mariel S Lavieri; Brent K Hollenbeck; Ted A Skolarus Journal: Urology Date: 2017-03-04 Impact factor: 2.649
Authors: J W Collins; A Hosseini; P Sooriakumaran; T Nyberg; R Sanchez-Salas; C Adding; Martin C Schumacher; N P Wiklund Journal: Curr Urol Rep Date: 2014-11 Impact factor: 3.092
Authors: Andrea Necchi; Gregory R Pond; Marc C Smaldone; Sumanta K Pal; Kevin Chan; Yu-Ning Wong; Rosalia Viterbo; Guru Sonpavde; Lauren C Harshman; Simon Crabb; Ajjai Alva; Simon Chowdhury; Ugo De Giorgi; Sandy Srinivas; Neeraj Agarwal; Aristotelis Bamias; Jack Baniel; Ali-Reza Golshayan; Sylvain Ladoire; Cora N Sternberg; Linda Cerbone; Evan Y Yu; Joaquim Bellmunt; Ulka Vaishampayan; Gunter Niegisch; Syed Hussain; Daniel W Bowles; Rafael Morales-Barrera; Matthew I Milowsky; Christine Theodore; Dominik R Berthold; Srikala S Sridhar; Thomas Powles; Jonathan E Rosenberg; Matthew D Galsky Journal: Eur Urol Focus Date: 2017-03-31
Authors: Jason F Flamiatos; Yiyi Chen; William E Lambert; Ann Martinez Acevedo; Thomas M Becker; Jasper C Bash; Christopher L Amling Journal: J Robot Surg Date: 2018-06-08
Authors: Bernard H Bochner; Guido Dalbagni; Daniel D Sjoberg; Jonathan Silberstein; Gal E Keren Paz; S Machele Donat; Jonathan A Coleman; Sheila Mathew; Andrew Vickers; Geoffrey C Schnorr; Michael A Feuerstein; Bruce Rapkin; Raul O Parra; Harry W Herr; Vincent P Laudone Journal: Eur Urol Date: 2014-12-08 Impact factor: 20.096
Authors: Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens Journal: Can Urol Assoc J Date: 2016-02-08 Impact factor: 1.862